{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T08:47:49Z","timestamp":1775292469599,"version":"3.50.1"},"reference-count":96,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Laboratory Medicine"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.cll.2021.07.002","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T01:07:51Z","timestamp":1634864871000},"page":"579-598","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Blood Product (Donor) Noninfectious and Infectious Testing and Modification"],"prefix":"10.1016","volume":"41","author":[{"given":"Tania","family":"Sarker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis M.","family":"Katz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan M.","family":"Bloch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruchika","family":"Goel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cll.2021.07.002_bib1","series-title":"Transfusion medicine and Hemostasis","first-page":"59","article-title":"Chapter 10 - serologic testing of donor products","author":"Peck","year":"2019"},{"issue":"11 Suppl 2","key":"10.1016\/j.cll.2021.07.002_bib2","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1111\/trf.12413","article-title":"The concept of \"confirmatory testing\" of donors for ABO and RhD","volume":"53","author":"Westhoff","year":"2013","journal-title":"Transfusion"},{"issue":"1","key":"10.1016\/j.cll.2021.07.002_bib3","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/trf.15004","article-title":"Prevalence and risk factors for RBC alloantibodies in blood donors in the recipient epidemiology and donor evaluation study-III (REDS-III)","volume":"59","author":"Karafin","year":"2019","journal-title":"Transfusion"},{"issue":"5","key":"10.1016\/j.cll.2021.07.002_bib4","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1097\/AOG.0b013e31826d7dc1","article-title":"Management and prevention of red cell alloimmunization in pregnancy: a systematic review","volume":"120","author":"Moise","year":"2012","journal-title":"Obstet Gynecol"},{"issue":"Suppl 2","key":"10.1016\/j.cll.2021.07.002_bib6","first-page":"1S","article-title":"Emerging infectious disease agents and their potential threat to transfusion safety","volume":"49","author":"Stramer","year":"2009","journal-title":"Transfusion"},{"key":"10.1016\/j.cll.2021.07.002_bib7","unstructured":"Technical Manual, 20th ed. Editors \u2013 Claudia S. Cohn, Meghan Delaney, Susan T. Johnson, Louis M. Katz. Publisher \u2013 AABB, Bethesda, Maryland, USA."},{"issue":"17","key":"10.1016\/j.cll.2021.07.002_bib8","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1182\/blood-2018-11-833996","article-title":"Prevention of transfusion-transmitted infections","volume":"133","author":"Busch","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.cll.2021.07.002_bib9","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/voxs.12082","article-title":"Infectious risks of blood transfusions: recent advances in testing technologies and new approaches to surveillance and decision-making","volume":"9","author":"Busch","year":"2014","journal-title":"Int Soc Blood Transfus ISBT Sci Ser"},{"issue":"4","key":"10.1016\/j.cll.2021.07.002_bib10","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1046\/j.1365-3148.2002.00387.x","article-title":"US NAT yield: where are we after 2 years?","volume":"12","author":"Stramer","year":"2002","journal-title":"Transfus Med"},{"issue":"2","key":"10.1016\/j.cll.2021.07.002_bib11","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1537-2995.2004.04215.x","article-title":"A\u00a0new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors","volume":"45","author":"Busch","year":"2005","journal-title":"Transfusion"},{"issue":"3","key":"10.1016\/j.cll.2021.07.002_bib12","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/trf.16250","article-title":"HIV, HCV, and HBV incidence and residual risk in US blood donors before and after implementation of the 12-month deferral policy for men who have sex with men","volume":"61","author":"Steele","year":"2021","journal-title":"Transfusion"},{"key":"10.1016\/j.cll.2021.07.002_bib13","series-title":"Title 21 (foods and drugs). Parts 610 and 630.3","year":"2020"},{"issue":"7","key":"10.1016\/j.cll.2021.07.002_bib14","doi-asserted-by":"crossref","first-page":"e00352","DOI":"10.1128\/JCM.00352-18","article-title":"Transfusion-transmitted infections: an update on product screening, diagnostic techniques, and the path ahead","volume":"56","author":"Dean","year":"2018","journal-title":"J\u00a0Clin Microbiol"},{"issue":"1","key":"10.1016\/j.cll.2021.07.002_bib15","doi-asserted-by":"crossref","first-page":"57","DOI":"10.7326\/M15-1329","article-title":"Emerging infections and blood safety in the 21st century","volume":"165","author":"Bloch","year":"2016","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.cll.2021.07.002_bib16","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1537-2995.1969.tb04909.x","article-title":"Transmission of syphilis by fresh blood components","volume":"9","author":"Chambers","year":"1969","journal-title":"Transfusion"},{"issue":"10","key":"10.1016\/j.cll.2021.07.002_bib17","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1111\/j.1537-2995.2010.02851.x","article-title":"Transfusion-associated infections: 50 years of relentless challenges and remarkable progress","volume":"50","author":"Perkins","year":"2010","journal-title":"Transfusion"},{"issue":"4","key":"10.1016\/j.cll.2021.07.002_bib18","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1537-2995.2009.02119.x","article-title":"A\u00a0test that won't die: the serologic test for syphilis","volume":"49","author":"Katz","year":"2009","journal-title":"Transfusion"},{"issue":"4","key":"10.1016\/j.cll.2021.07.002_bib19","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1537-2995.2008.02042.x","article-title":"Current value of serologic test for syphilis as a surrogate marker for blood-borne viral infections among blood donors in the United States","volume":"49","author":"Zou","year":"2009","journal-title":"Transfusion"},{"issue":"2","key":"10.1016\/j.cll.2021.07.002_bib21","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1001\/jama.1970.03170020025005","article-title":"Posttransfusion hepatitis after open-heart operations. Incidence after the administration of blood from commercial and volunteer donor populations","volume":"211","author":"Walsh","year":"1970","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.cll.2021.07.002_bib22","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1182\/blood-2008-07-077370","article-title":"The hazards of blood transfusion in historical perspective","volume":"112","author":"Alter","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cll.2021.07.002_bib23","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-104-4-488","article-title":"Antibody to hepatitis B core antigen as a paradoxical marker for non-A, non-B hepatitis agents in donated blood","volume":"104","author":"Koziol","year":"1986","journal-title":"Ann Intern Med"},{"issue":"17","key":"10.1016\/j.cll.2021.07.002_bib24","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJM198104233041701","article-title":"Serum alanine aminotransferase of donors in relation to the risk of non-A, non-B hepatitis in recipients: the transfusion-transmitted viruses study","volume":"304","author":"Aach","year":"1981","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.cll.2021.07.002_bib25","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1001\/jama.1981.03320060032017","article-title":"Donor transaminase and recipient hepatitis. Impact on blood transfusion services","volume":"246","author":"Alter","year":"1981","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.cll.2021.07.002_bib26","doi-asserted-by":"crossref","first-page":"644","DOI":"10.7326\/0003-4819-115-8-644","article-title":"Descartes before the horse: I clone, therefore I am: the hepatitis C virus in current perspective","volume":"115","author":"Alter","year":"1991","journal-title":"Ann Intern Med"},{"issue":"22","key":"10.1016\/j.cll.2021.07.002_bib27","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1056\/NEJM198911303212202","article-title":"Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis","volume":"321","author":"Alter","year":"1989","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cll.2021.07.002_bib28","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jcv.2018.05.009","article-title":"An ultra-sensitive Abbott ARCHITECT((R)) assay for the detection of hepatitis B virus surface antigen (HBsAg)","volume":"105","author":"Lou","year":"2018","journal-title":"J\u00a0Clin Virol"},{"issue":"26","key":"10.1016\/j.cll.2021.07.002_bib29","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJM199606273342601","article-title":"The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study","volume":"334","author":"Schreiber","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cll.2021.07.002_bib30","series-title":"Transfusion medicine and hemostasis","first-page":"63","article-title":"Chapter 11 - overview of infectious disease testing","author":"Jimenez","year":"2019"},{"key":"10.1016\/j.cll.2021.07.002_bib31","series-title":"Final guidance for industry: use of nucleic acid tests on pooled and individual samples from donors of whole blood and blood components, including source plasma, to reduce the risk of transmission of hepatitis B virus","year":"2012"},{"issue":"3","key":"10.1016\/j.cll.2021.07.002_bib32","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1056\/NEJMoa1007644","article-title":"Nucleic acid testing to detect HBV infection in blood donors","volume":"364","author":"Stramer","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.cll.2021.07.002_bib33","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1046\/j.1537-2995.1991.31191096183.x","article-title":"Risk of human immunodeficiency virus (HIV) transmission by blood transfusions before the implementation of HIV-1 antibody screening. The Transfusion Safety Study Group","volume":"31","author":"Busch","year":"1991","journal-title":"Transfusion"},{"issue":"4","key":"10.1016\/j.cll.2021.07.002_bib34","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1046\/j.1537-2995.1994.34494233574.x","article-title":"Duration of time from onset of human immunodeficiency virus type 1 infectiousness to development of detectable antibody. The HIV Seroconversion Study Group","volume":"34","author":"Petersen","year":"1994","journal-title":"Transfusion"},{"issue":"8","key":"10.1016\/j.cll.2021.07.002_bib35","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1056\/NEJMoa040085","article-title":"Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing","volume":"351","author":"Stramer","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.cll.2021.07.002_bib36","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1423-0410.2011.01506.x","article-title":"International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009","volume":"102","author":"Roth","year":"2012","journal-title":"Vox Sang"},{"issue":"7","key":"10.1016\/j.cll.2021.07.002_bib37","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1111\/j.1537-2995.2010.02621.x","article-title":"Prevalence, incidence, and residual risk of major blood-borne infections among apheresis collections to the American Red Cross Blood Services, 2004 through 2008","volume":"50","author":"Zou","year":"2010","journal-title":"Transfusion"},{"key":"10.1016\/j.cll.2021.07.002_bib38","series-title":"Guidance for industry: nucleic acid testing (NAT) for human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV): testing, product disposition, and donor deferral and reentry","year":"2017"},{"issue":"10","key":"10.1016\/j.cll.2021.07.002_bib39","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1046\/j.1537-2995.1999.39101141.x","article-title":"Direct HIV testing in blood donations: variation of the yield with detection threshold and pool size","volume":"39","author":"Le Corfec","year":"1999","journal-title":"Transfusion"},{"key":"10.1016\/j.cll.2021.07.002_bib40","series-title":"Guidance for industry: revised recommendations for reducing the risk of human immunodeficiency virus transmission by blood and blood products","year":"2020"},{"issue":"6","key":"10.1016\/j.cll.2021.07.002_bib41","doi-asserted-by":"crossref","first-page":"448","DOI":"10.7326\/0003-4819-118-6-199303150-00009","article-title":"Guidelines for counseling persons infected with human T-lymphotropic virus type I (HTLV-I) and type II (HTLV-II). Centers for Disease Control and Prevention and the U.S.P.H.S. Working Group","volume":"118","year":"1993","journal-title":"Ann Intern Med"},{"issue":"Suppl 1","key":"10.1016\/j.cll.2021.07.002_bib42","doi-asserted-by":"crossref","first-page":"S215","DOI":"10.1097\/00042560-199600001-00032","article-title":"The clinical epidemiology of human T-lymphotropic virus type II (HTLV-II)","volume":"13","author":"Murphy","year":"1996","journal-title":"J\u00a0Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"10.1016\/j.cll.2021.07.002_bib43","series-title":"HTLV type I and type II. NORD","year":"2012"},{"issue":"5","key":"10.1016\/j.cll.2021.07.002_bib45","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1537-2995.2006.00788.x","article-title":"Effectiveness of human T-lymphotropic virus (HTLV) recipient tracing (lookback) and the current HTLV-I and -II confirmatory algorithm, 1999 to 2004","volume":"46","author":"Stramer","year":"2006","journal-title":"Transfusion"},{"issue":"3","key":"10.1016\/j.cll.2021.07.002_bib46","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1053\/tmrv.1997.0110173","article-title":"The clinical relevance of HTLV type I and II in transfusion medicine","volume":"11","author":"Vrielink","year":"1997","journal-title":"Transfus Med Rev"},{"issue":"1","key":"10.1016\/j.cll.2021.07.002_bib47","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/2110-5820-3-2","article-title":"Age of red blood cells and transfusion in critically ill patients","volume":"3","author":"Aubron","year":"2013","journal-title":"Ann Intensive Care"},{"issue":"5","key":"10.1016\/j.cll.2021.07.002_bib48","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.ahj.2009.12.045","article-title":"Duration of red cell storage before transfusion and in-hospital mortality","volume":"159","author":"Eikelboom","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.cll.2021.07.002_bib49","series-title":"Guidance for industry: use of serological tests to reduce the risk of transfusion-transmitted human T-Lymphotropic virus types I and II (HTLV-I\/II)","year":"2020"},{"issue":"10","key":"10.1016\/j.cll.2021.07.002_bib50","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1111\/j.1537-2995.2010.02686.x","article-title":"Cost-effectiveness of screening the US blood supply for Trypanosoma cruzi","volume":"50","author":"Agapova","year":"2010","journal-title":"Transfusion"},{"key":"10.1016\/j.cll.2021.07.002_bib51","series-title":"Guidance for industry: use of serological tests to reduce the risk of transmission of Trypanosoma cruzi infection in blood and blood components","year":"2017"},{"issue":"2","key":"10.1016\/j.cll.2021.07.002_bib52","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1537-2995.2012.03742.x","article-title":"Emerging infectious agents and the nation's blood supply: responding to potential threats in the 21st century","volume":"53","author":"Glynn","year":"2013","journal-title":"Transfusion"},{"issue":"24","key":"10.1016\/j.cll.2021.07.002_bib53","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJM200106143442401","article-title":"The outbreak of West Nile virus infection in the New York City area in 1999","volume":"344","author":"Nash","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.cll.2021.07.002_bib54","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1056\/NEJMoa030969","article-title":"Transmission of West Nile virus through blood transfusion in the United States in 2002","volume":"349","author":"Pealer","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.cll.2021.07.002_bib55","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.tmrv.2015.03.001","article-title":"Keeping blood transfusion safe from west nile virus: American red cross experience, 2003 to 2012","volume":"29","author":"Dodd","year":"2015","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.cll.2021.07.002_bib56","series-title":"Guidance for industry: use of nucleic acid tests to reduce the risk of transmission of west nile virus from donors of whole blood and blood components intended for transfusion","year":"2009"},{"issue":"16","key":"10.1016\/j.cll.2021.07.002_bib58","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMra1602113","article-title":"Zika virus","volume":"374","author":"Petersen","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.cll.2021.07.002_bib59","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.3201\/eid2207.151990","article-title":"A\u00a0literature review of zika virus","volume":"22","author":"Plourde","year":"2016","journal-title":"Emerg Infect Dis"},{"issue":"20","key":"10.1016\/j.cll.2021.07.002_bib60","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMsr1604338","article-title":"Zika virus and birth defects--reviewing the evidence for causality","volume":"374","author":"Rasmussen","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.cll.2021.07.002_bib61","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1056\/NEJMoa1602412","article-title":"Zika virus infection in pregnant women in rio de Janeiro","volume":"375","author":"Brasil","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"10047","key":"10.1016\/j.cll.2021.07.002_bib62","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S0140-6736(16)30902-3","article-title":"Congenital Zika virus syndrome in Brazil: a case series of the first 1501 livebirths with complete investigation","volume":"388","author":"Franca","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.cll.2021.07.002_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJMp1605367","article-title":"Zika and the risk of microcephaly","volume":"375","author":"Johansson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.cll.2021.07.002_bib64","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1182\/blood-2016-09-737981","article-title":"Zika virus in asymptomatic blood donors in Martinique","volume":"129","author":"Gallian","year":"2017","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.cll.2021.07.002_bib65","doi-asserted-by":"crossref","first-page":"20761","DOI":"10.2807\/1560-7917.ES2014.19.14.20761","article-title":"Potential for Zika virus transmission through blood transfusion demonstrated during an outbreak in French Polynesia, November 2013 to February 2014","volume":"19","author":"Musso","year":"2014","journal-title":"Euro Surveill"},{"issue":"24","key":"10.1016\/j.cll.2021.07.002_bib66","doi-asserted-by":"crossref","first-page":"627","DOI":"10.15585\/mmwr.mm6524e2","article-title":"Screening of blood donations for zika virus infection - Puerto Rico, April 3-June 11, 2016","volume":"65","author":"Kuehnert","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"10.1016\/j.cll.2021.07.002_bib67","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1182\/blood-2016-12-751925","article-title":"Zika virus in the blood supply","volume":"129","author":"Benjamin","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.cll.2021.07.002_bib69","series-title":"Guidance for industry: revised recommendations for reducing the risk of zika virus transmission by blood and blood components","year":"2018"},{"issue":"3","key":"10.1016\/j.cll.2021.07.002_bib70","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3390\/pathogens8030102","article-title":"Persistence of Babesia microti infection in humans","volume":"8","author":"Bloch","year":"2019","journal-title":"Pathogens"},{"issue":"23","key":"10.1016\/j.cll.2021.07.002_bib71","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1056\/NEJMoa1600897","article-title":"Screening for Babesia microti in the U.S. Blood supply","volume":"375","author":"Moritz","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cll.2021.07.002_bib72","series-title":"Guidance for industry: recommendations for reducing the risk of transfusion-transmitted babesiosis","year":"2019"},{"issue":"8","key":"10.1016\/j.cll.2021.07.002_bib73","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1111\/trf.14912","article-title":"Assessing the risk of Babesia to the United States blood supply using a risk-based decision-making approach: report of AABB's Ad Hoc Babesia Policy Working Group (original report)","volume":"58","author":"Ward","year":"2018","journal-title":"Transfusion"},{"issue":"10","key":"10.1016\/j.cll.2021.07.002_bib74","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1111\/trf.14280","article-title":"Inactivation of Babesia microti in red blood cells and platelet concentrates","volume":"57","author":"Tonnetti","year":"2017","journal-title":"Transfusion"},{"issue":"12","key":"10.1016\/j.cll.2021.07.002_bib75","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1111\/j.1537-2995.2009.02429.x","article-title":"Transfusion-transmitted babesiosis in the United States: summary of a workshop","volume":"49","author":"Gubernot","year":"2009","journal-title":"Transfusion"},{"key":"10.1016\/j.cll.2021.07.002_bib76","series-title":"Guidance for industry: revised recommendations to reduce the risk of transfusion-transmitted malaria","year":"2020"},{"issue":"2","key":"10.1016\/j.cll.2021.07.002_bib77","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1537-2995.2007.01114.x","article-title":"Return behavior of blood donors after expiration of a 1-year malarial travel deferral","volume":"47","author":"Katz","year":"2007","journal-title":"Transfusion"},{"issue":"11","key":"10.1016\/j.cll.2021.07.002_bib78","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1111\/j.1537-2995.2009.02290.x","article-title":"Risk for malaria in United States donors deferred for travel to malaria-endemic areas","volume":"49","author":"Spencer","year":"2009","journal-title":"Transfusion"},{"issue":"10029","key":"10.1016\/j.cll.2021.07.002_bib79","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/S0140-6736(16)00581-X","article-title":"Effect of Plasmodium inactivation in whole blood on the incidence of blood transfusion-transmitted malaria in endemic regions: the African Investigation of the Mirasol System (AIMS) randomised controlled trial","volume":"387","author":"Allain","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.cll.2021.07.002_bib82","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/trf.15751","article-title":"No evidence of transfusion transmitted sporadic Creutzfeldt-Jakob disease: results from a bi-national cohort study","volume":"60","author":"Holmqvist","year":"2020","journal-title":"Transfusion"},{"issue":"3","key":"10.1016\/j.cll.2021.07.002_bib83","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/vox.12631","article-title":"Creutzfeldt-Jakob disease and blood transfusion safety","volume":"113","author":"Seed","year":"2018","journal-title":"Vox Sang"},{"issue":"8","key":"10.1016\/j.cll.2021.07.002_bib84","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1111\/trf.14145","article-title":"Creutzfeldt-Jakob disease lookback study: 21 years of surveillance for transfusion transmission risk","volume":"57","author":"Crowder","year":"2017","journal-title":"Transfusion"},{"key":"10.1016\/j.cll.2021.07.002_bib85","series-title":"Guidance for industry: recommendations to reduce the possible risk of transmission of creutzfeldt-jakob disease and variant creutzfeldt-jakob disease by blood and blood components","year":"2020"},{"issue":"1","key":"10.1016\/j.cll.2021.07.002_bib86","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.tmrv.2007.09.003","article-title":"Transfusion transmission of human prion diseases","volume":"22","author":"Zou","year":"2008","journal-title":"Transfus Med Rev"},{"issue":"8","key":"10.1016\/j.cll.2021.07.002_bib87","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1111\/trf.14789","article-title":"The epidemiology of bacterial culture-positive and septic transfusion reactions at a large tertiary academic center: 2009 to 2016","volume":"58","author":"Erony","year":"2018","journal-title":"Transfusion"},{"issue":"9","key":"10.1016\/j.cll.2021.07.002_bib88","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1111\/trf.15978","article-title":"Secondary bacterial culture of platelets to mitigate transfusion-associated sepsis: a 3-year analysis at a large academic institution","volume":"60","author":"Fenwick","year":"2020","journal-title":"Transfusion"},{"issue":"10","key":"10.1016\/j.cll.2021.07.002_bib89","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1111\/trf.14306","article-title":"Residual risk of bacterial contamination: what are the options?","volume":"57","author":"Bloch","year":"2017","journal-title":"Transfusion"},{"issue":"4","key":"10.1016\/j.cll.2021.07.002_bib90","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood-2015-07-655944","article-title":"Detection of septic transfusion reactions to platelet transfusions by active and passive surveillance","volume":"127","author":"Hong","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cll.2021.07.002_bib91","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1182\/blood-2015-12-685198","article-title":"Transfusion-related sepsis: a silent epidemic","volume":"127","author":"Benjamin","year":"2016","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.cll.2021.07.002_bib92","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1111\/j.1537-2995.2009.02348.x","article-title":"Bacterial culture reduces but does not eliminate the risk of septic transfusion reactions to single-donor platelets","volume":"49","author":"Fuller","year":"2009","journal-title":"Transfusion"},{"key":"10.1016\/j.cll.2021.07.002_bib93","series-title":"Fatalities reported to FDA following blood collection and transfusion","year":"2018"},{"key":"10.1016\/j.cll.2021.07.002_bib94","series-title":"Guidance for industry: bacterial risk control strategies for blood collection establishments and transfusion services to enhance the safety and availability of platelets for transfusion","year":"2020"},{"issue":"3","key":"10.1016\/j.cll.2021.07.002_bib95","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.tmrv.2005.02.002","article-title":"Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis","volume":"19","author":"Vamvakas","year":"2005","journal-title":"Transfus Med Rev"},{"issue":"1","key":"10.1016\/j.cll.2021.07.002_bib96","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1423-0410.2009.01228.x","article-title":"Survey of current practice for prevention of transfusion-transmitted cytomegalovirus in the United States: leucoreduction vs. cytomegalovirus-seronegative","volume":"98","author":"Smith","year":"2010","journal-title":"Vox Sang"},{"issue":"4","key":"10.1016\/j.cll.2021.07.002_bib97","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/tme.12437","article-title":"Transfusion-transmitted CMV infection - current knowledge and future perspectives","volume":"27","author":"Ziemann","year":"2017","journal-title":"Transfus Med"},{"issue":"4","key":"10.1016\/j.cll.2021.07.002_bib98","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1537-2995.2009.02486.x","article-title":"Direct assessment of cytomegalovirus transfusion-transmitted risks after universal leukoreduction","volume":"50","author":"Wu","year":"2010","journal-title":"Transfusion"},{"issue":"5","key":"10.1016\/j.cll.2021.07.002_bib99","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.hoc.2019.05.001","article-title":"Pathogen reduction: the state of the science in 2019","volume":"33","author":"Gehrie","year":"2019","journal-title":"Hematol Oncol Clin North Am"},{"issue":"12","key":"10.1016\/j.cll.2021.07.002_bib100","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1111\/trf.13259","article-title":"Risks associated with red blood cell transfusions: potential benefits from application of pathogen inactivation","volume":"55","author":"Kleinman","year":"2015","journal-title":"Transfusion"},{"issue":"7","key":"10.1016\/j.cll.2021.07.002_bib101","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1111\/j.1537-2995.2012.03928.x","article-title":"A\u00a0patient-oriented risk-benefit analysis of pathogen-inactivated blood components: application to apheresis platelets in the United States","volume":"53","author":"Kleinman","year":"2013","journal-title":"Transfusion"},{"issue":"3","key":"10.1016\/j.cll.2021.07.002_bib103","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/trf.12996","article-title":"Pathogen inactivation or pathogen reduction: proposal for standardization of nomenclature","volume":"55","author":"Lozano","year":"2015","journal-title":"Transfusion"},{"issue":"10 Pt 2","key":"10.1016\/j.cll.2021.07.002_bib105","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1111\/trf.12213","article-title":"Hepatitis B virus testing by minipool nucleic acid testing: does it improve blood safety?","volume":"53","author":"Stramer","year":"2013","journal-title":"Transfusion"}],"container-title":["Clinics in Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271221000469?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271221000469?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T23:58:24Z","timestamp":1759449504000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272271221000469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":96,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0272271221000469"],"URL":"https:\/\/doi.org\/10.1016\/j.cll.2021.07.002","relation":{},"ISSN":["0272-2712"],"issn-type":[{"value":"0272-2712","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blood Product (Donor) Noninfectious and Infectious Testing and Modification","name":"articletitle","label":"Article Title"},{"value":"Clinics in Laboratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cll.2021.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}